Alphabetic Index FY2027

D17.79

Benign lipomatous neoplasm of other sites

FY2027Chapter 2: Neoplasms/D10–D36 Benign neoplasms, except benign neuroendocrine tumors

BillableComplete code, valid to report
    Care settingsHome Health Primary · MMTA - Infectious Disease, Neoplasms, and Blood-Forming DiseasesIPF Comorbidity · Oncology Treatment

    D17.79 (also written D1779) is a billable ICD-10-CM diagnosis code for benign lipomatous neoplasm of other sites. It is part of the FY2027 code set, effective October 1, 2026. It is one of the 16 codes in category D17 (Benign lipomatous neoplasm). The Alphabetic Index lists it under 5 entries.

    Care settings

    How CMS programs treat this code. These are CMS claim edits and list entries, not coverage or eligibility rules.

    Home Health Primary

    Accepted as the primary (principal) diagnosis on a home health claim. The Home Health Grouper assigns it to the MMTA - Infectious Disease, Neoplasms, and Blood-Forming Diseases clinical group.

    Source: CMS Home Health Grouper Software v07.2.26, effective October 1, 2026

    IPF Comorbidity

    On the CMS IPF comorbidity list.

    Comorbidity categoryFactor
    Oncology Treatment1.44
    It counts as a comorbidity when reported as a secondary diagnosis and actively treated during the stay. An IPF receives only one adjustment within a category and can receive adjustments in more than one category.

    Source: CMS IPF PPS FY 2027 final rule (CMS-1847-F), Addendum B-3 (comorbidity codes with adjustment factor); effective for discharges on or after October 1, 2026

    Inclusion terms

    Conditions classified to this code.

    This code
    • Benign lipomatous neoplasm of peritoneum
    • Benign lipomatous neoplasm of retroperitoneum

    Notes

    Also from chapter/block level (8 notes)
    Inherited from Chapter 2 Neoplasms
    • Functional activity
    • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
    • Morphology [Histology]
    • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
    • Primary malignant neoplasms overlapping site boundaries
    • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
    • Malignant neoplasm of ectopic tissue
    • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).

    Alphabetic Index terms

    Terms the official Alphabetic Index lists for this code. 5 entries